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Background: Left ventricular ejection fraction (LVEF) is the most widely used parameter 
to evaluate the cardiac function in patients with heart failure (HF). However, the association 
between LVEF and contrast-induced nephropathy (CIN) is still controversial. Therefore, the aim 
of this study is to evaluate the association of LVEF with CIN and long-term mortality following 
coronary angiography (CAG) or intervention in patients with HF.
Methods: We analyzed 1,647 patients with HF (New York Heart Association [NYHA] or Killip 
class .1) undergoing CAG or intervention, including 207 (12.57%) patients with reduced LVEF 
(HFrEF), 238 (14.45%) with mid-range LVEF (HFmrEF) and 1,202 (72.98%) with preserved 
LVEF (HFpEF). CIN was defined as an absolute increase of $0.5 mg/dL or a relative increase 
of $25% from baseline serum creatinine within 48–72 h after contrast medium exposure. 
Multivariable logistic regression and Cox proportional hazards regression analyses were per-
formed to identify the association between LVEF, CIN and long-term mortality, respectively.
Results: Overall, 225 patients (13.7%) developed CIN. Individuals with lower LVEF were more 
likely to develop CIN (HFrEF, HFmrEF and HFpEF: 18.4%, 21.8% and 11.2%, respectively; 
P,0.001), but without a significant trend after adjusting for the confounding factors (HFrEF 
vs HFpEF: odds ratio [OR] =1.01; HFmrEF vs HFpEF: OR =1.31; all P.0.05). However, 
advanced HF (NYHA class .2 or Killip class .1) was an independent predictor of CIN (adjusted 
OR =1.54, 95% confidence interval [CI], 1.07–2.22; P=0.019). During the mean follow-up of 
2.3 years, reduced LVEF (HFrEF group) was significantly associated with increased mortality 
(HFrEF vs HFpEF: adjusted hazard ratio =2.88, 95% CI, 1.77–4.69; P,0.001).
Conclusion: In patients with HF undergoing CAG or intervention, not worsened LVEF but 
advanced HF was associated with an increased risk of CIN. In addition, reduced LVEF was an 
independent predictor of long-term mortality following cardiac catheterization.
Keywords: cardiac catheterization, contrast-induced nephropathy, left ventricular ejection 
fraction, heart failure
Introduction
With the development of interventional technology and medication strategies, the 
number of cardiac catheterization procedures being performed continues to grow 
rapidly.1 Simultaneously, the incidence of contrast-induced nephropathy (CIN), a 
common and well-known complication which occurs following coronary angiography 
(CAG) or percutaneous coronary intervention (PCI) and is significantly associated with 
renal and cardiovascular adverse events and long-term mortality, has also increased 
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gradually.2,3 Since the effective treatment measures for CIN 
are unknown, risk identification is important for ensuring that 
high-risk patients receive appropriate prophylactic measures 
and postoperative monitoring.4
Heart failure (HF) is a common and deteriorating condi-
tion, which has a high prevalence of ischemic origin.5 With 
the advancement of HF or cardiac impairment, adverse 
hemodynamic state results in inadequate renal perfusion 
and accelerates the renal impairment after contrast medium 
(CM) administration.6,7 Previous studies indicated that HF 
is one of the critical factors influencing the development of 
CIN.8,9 Left ventricular ejection fraction (LVEF) is another 
parameter that reflects the cardiac function and a useful 
term to categorize the type of HF, such as HF with reduced 
ejection fraction (HFrEF; EF ,40%), HF with mid-range 
ejection fraction (HFmrEF; EF 40%–49%) and HF with 
preserved ejection fraction (HFpEF; EF $50%).10 However, 
the association between LVEF and the risk of CIN is still 
controversial.11–14 Therefore, the purpose of our study was 
to analyze the association of LVEF with CIN and long-term 
mortality following CAG/PCI in patients with HF.
Methods
study population
This prospective observational study was conducted at the 
Guangdong General Hospital from April 2009 to December 
2013. We included patients aged .18 years who had HF, 
defined as New York Heart Association (NYHA) or Killip 
class .1, and were undergoing PCI/CAG. Based on the 
protocol, exclusion criteria included pregnancy, malignancy, 
cardiovascular surgery or endovascular repair, end-stage 
renal disease or renal replacement, treatment with nephropro-
tective (eg, N-acetylcysteine) or nephrotoxic (eg, glucocor-
ticoids, aminoglycosides) drugs and exposure to CM within 
the previous 7 days. In addition, patients who had missing 
preoperative or postoperative creatinine values (n=87) and 
LVEF (n=448) were excluded.
Biochemical investigations
Serum creatinine (SCr) concentrations were measured at 
admission and within 24, 48 and 72 h after CM administra-
tion. Other biochemical indicators were measured in the 
morning prior to the procedure. The Modification of Diet in 
Renal Disease equation was used to calculate the estimated 
glomerular filtration rate (eGFR),15 and the echocardiography 
examination was used to evaluate the LVEF. A baseline 
eGFR ,60 mL/min/1.73 m2 was defined as renal insuf-
ficiency.16 Furthermore, NYHA class .2 or Killip class .1 
was defined as advanced HF.17,18
Cardiac catheterization
Cardiac catheterization was performed according to the 
standard clinical practice, by experienced interventional 
cardiologists. Non-ionic, low-osmolality CM was used for all 
patients. The type of stents was selected by the interventional 
cardiologists according to operative requirements. All patients 
received intravenous infusion of normal saline 2–12 h before 
and 6–24 h after the procedure at a speed of 0.5–1.0 mL/kg/h. 
The hydration time and speed and the clinical medication 
were chosen based on the patient condition.
Clinical end points and follow-up
The primary end point of this study was the development 
of CIN, defined as an absolute increase of $0.5 mg/dL or 
a relative increase of $25% from baseline SCr level within 
48–72 h after CM exposure (CIN
0.5 or 25%
).19 Additional end 
point included another criteria of CIN, defined as an abso-
lute increase of $0.3 mg/dL or a relative increase of $50% 
(CIN
0.3 or 50%
) and an absolute increase of $0.5 mg/dL 
(CIN
0.5
),20 and all-cause mortality.
All patients included in this study were followed up 
by telephone or office visits at 1, 6, 12, 24 and 36 months 
after discharge. Adverse events were recorded on the case 
report form.
This study was performed according to the Declaration 
of Helsinki, and the ethics committee of the Guangdong 
General Hospital approved the study protocol. Written 
informed consent was obtained from the patients involved 
in the study.
statistical analysis
Patients were divided into three groups based on the level 
of LVEF according to the 2016 European Society of 
Cardiology guideline for HF.10 For continuous variables, 
ANOVA was used for normally distributed data (described 
as mean ± standard deviation), and Wilcoxon rank-sum 
test was conducted for non-normal distributions (described 
as interquartile range). For categorical variables, χ2 test or 
Fisher’s exact test was used (described as absolute values 
and percentages). Multivariable logistic regression and Cox 
proportional hazards regression analyses were performed to 
identify the association of LVEF with CIN and long-term 
mortality, respectively. HFpEF was considered as the refer-
ence group. The effect of HFmrEF and HFrEF on outcomes 
was estimated and was compared with the reference group. 
Kaplan–Meier method was used to describe the all-cause 
mortality by log-rank tests. All statistical analyses were per-
formed with SPSS software version 22.0 (IBM Corporation, 
Armonk, NY, USA) and R software (version 3.1.2; R Core 
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Team, Vienna, Austria). A two-tailed P,0.05 was considered 
statistically significant.
Results
Baseline demographics and characteristics
A total of 1,647 patients with HF undergoing CAG/PCI were 
analyzed, including 207 (12.57%) patients with HFrEF, 238 
(14.45%) with HFmrEF and 1,202 (72.98%) with HFpEF. 
The baseline demographics and characteristics of patients 
are listed in Table 1.
Compared to the patients with HFpEF, patients with 
HFrEF were more likely to have advanced HF, renal insuf-
ficiency and prior myocardial fraction. Furthermore, those 
in the HFrEF group had lower systolic blood pressure on 
admission and were less likely to have a history of hyper-
tension. However, age, gender, smoking, hyperlipidemia 
and history of coronary artery bypass grafting were similar 
among the three groups.
On admission, patients with HFrEF had higher SCr and 
N-terminal pro-brain natriuretic peptide concentrations, but 
Table 1 Baseline characteristics according to the left ventricular ejection fraction group
Variables HFrEF (N=207) HFmrEF (N=238) HFpEF (N=1,202) P-values
Demographics
age (years) 64.20±10.75 65.05±11.44 64.90±10.52 0.651
Female (%) 43 (20.8) 51 (21.4) 319 (26.5) 0.078
sBP (mmhg) 122.62±20.49 123.99±20.65 132.50±20.61 ,0.001
DBP (mmhg) 76.65±12.03 73.98±12.80 76.16±11.78 0.023
advanced hF, n (%) 115 (55.6) 115 (48.3) 271 (22.5) ,0.001
Medical history, n (%)
smoking 84 (40.6) 106 (44.5) 442 (36.8) 0.062
hypertension 98 (47.3) 136 (57.1) 775 (64.5) ,0.001
Diabetes mellitus 57 (27.5) 64 (26.9) 311 (25.9) 0.854
hyperlipidemia 26 (12.6) 26 (10.9) 175 (14.6) 0.286
Prior Mi 44 (21.3) 55 (23.1) 103 (8.6) ,0.001
Prior CaBg 2 (1.0) 3 (1.3) 12 (1.0) 0.931
Renal insufficiency 71 (34.3) 75 (31.5) 239 (19.9) ,0.001
laboratory index
sCr (µmol/l) 107.50±46.41 101.84±37.05 91.65±33.06 ,0.001
egFR (ml/min/1.73 m2) 70.88±25.99 73.39±26.11 79.79±25.01 ,0.001
nT-proBnP (pg/ml) 5,050.16±6,454.23 2,844.92±4,201.42 1,108.34±3,421.70 ,0.001
lVeF (%) 32.01±5.74 44.49±3.00 63.48±6.94 ,0.001
Tg (mmol/l) 1.31±0.82 1.41±0.69 1.55±1.25 0.072
ChO (mmol/l) 4.29±1.05 4.50±1.11 4.39±1.16 0.361
lDl (mmol/l) 2.57±0.84 2.81±0.94 2.61±0.95 0.071
hDl (mmol/l) 0.94±0.29 0.87±0.25 1.03±2.47 0.721
hba1c (%) 6.74±1.38 6.80±1.60 6.55±1.31 0.030
hgB (g/l) 132.41±17.98 131.17±17.65 131.50±16.56 0.749
anemia, n (%) 67 (32.4) 94 (39.5) 420 (34.9) 0.262
Perioperative medications, n (%)
aCei/aRB 181 (87.4) 206 (86.6) 1,053 (87.6) 0.905
β-blockers 157 (75.8) 198 (83.2) 1,015 (84.4) 0.009
statins 192 (92.8) 230 (96.6) 1,160 (96.5) 0.033
Diuretics 116 (56.0) 97 (40.8) 176 (14.6) ,0.001
angiographic and procedural characteristics
emergent PCi, n (%) 36 (17.4) 64 (26.9) 126 (10.5) ,0.001
CM volume (ml) 124.30±69.76 140.11±69.99 133.84±66.49 0.046
CM volume .100 ml 101 (48.8) 144 (60.5) 687 (57.2) 0.034
stents length (mm) 32.69±36.07 39.91±37.48 37.22±33.02 0.078
hydration volume ml 855.19±536.83 894.70±492.87 801.85±464.86 0.014
Mehran risk score 8.76±6.09 8.85±5.62 5.86±4.33 ,0.001
Abbreviations: hFreF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; hFpeF, heart failure with preserved ejection 
fraction; sBP, systolic blood pressure; DBP, diastolic blood pressure; hF, heart failure; Mi, myocardial infarction; CaBg, coronary artery bypass grafting; sCr, serum 
creatinine; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction; TG, triglyceride; CHO, 
cholesterol; lDl, low-density lipoprotein; hDl, high-density lipoprotein; hba1c, hemoglobin a1c; hgB, hemoglobin; aCei, angiotensin-converting enzyme inhibitor; aRB, 
angiotensin receptor blocker; PCi, percutaneous coronary intervention; CM, contrast medium.
Therapeutics and Clinical Risk Management 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
890
Wang et al
lower eGFR and LVEF level. In addition, those patients 
were more likely to be on diuretics and less likely to be on 
β-blockers and stains than the other two groups. Furthermore, 
the prevalence of emergency PCI and the volume of CM were 
highest in the patients with HFmrEF.
incidence of Cin and in-hospital 
outcomes
Overall, 225 patients (13.7%) developed CIN, and the inci-
dence of CIN
0.5 or 25%
 was different among the LVEF groups 
(HFrEF, HFmrEF and HFpEF: 18.4%, 21.8% and 11.2%, 
respectively; P,0.001). Similar trend was observed in the 
incidence of CIN
0.3 or 50%
 or CIN
0.5
 (Table 2 and Figure 1).
Furthermore, patients with HFrEF were more likely to 
experience death (HFrEF, HFmrEF and HFpEF: 5.8%, 5.5% 
and 1.0%, respectively; P,0.001) and hypotension (HFrEF, 
HFmrEF and HFpEF: 11.1%, 9.2% and 2.1%, respectively; 
P,0.001). In addition, patients with lower LVEF had a sig-
nificantly higher rate of requirement of intra-aortic balloon 
pump (IABP) (HFrEF, HFmrEF and HFpEF: 14.0%, 12.2% 
and 2.9%, respectively; P,0.001) and renal replacement 
therapy (HFrEF, HFmrEF and HFpEF: 3.4%, 2.5% and 0.7%, 
respectively; P=0.002) (Table 2).
association of lVeF with Cin
After adjusting for the confounders, including age .75 years, 
hypertension, diabetes mellitus, renal insufficiency, advanced 
HF, prior myocardial infarction, emergency PCI, CM 
volume .100 mL, hypotension and use of stains, diuretics 
and IABP, multivariate logistic regression results revealed 
that individuals with lower LVEF were not at significantly 
increased risk of CIN compared with the highest LVEF 
group (HFrEF vs HFpEF: odds ratio [OR] =1.01, 95% 
confidence interval [CI], 0.69–1.74; P=0.700; HFmrEF vs 
HFpEF: OR =1.31, 95% CI, 0.87–1.96; P=0.194). Similar 
results were demonstrated for CIN
0.3 or 50%
 or CIN
0.5
. However, 
age .75 years, advanced HF, emergency PCI and use of 
IABP were the significantly independent risk factors for CIN 
in different criteria (Table 3).
association between lVeF, Cin and long-
term mortality
The mean follow-up period was 2.30±0.93 years. Log-rank 
analyses indicated that patients with lower LVEF were 
associated with higher mortality rate (log-rank, P,0.001). 
The Kaplan–Meier curve is shown in Figure 2. After adjust-
ing for the confounders which were associated with long-
term mortality, multivariate Cox regression showed that 
HFrEF was an independent predictor of mortality (HFrEF 
vs HFpEF: adjusted hazard ratio [HR] =2.88, 95% CI, 
1.77–4.69; P,0.001; HFmrEF vs HFpEF: HR =1.55, 95% 
CI, 0.95–2.53; P=0.079) (Table 4).
Moreover, patients who developed CIN
0.5 or 25%
 had higher 
rate of all-cause mortality than those without during the 
follow-up. Similar results were found in those who developed 
CIN
0.3 or 50%
 or CIN
0.5
 (Figure 3).
Discussion
To our knowledge, this is the first study to describe the 
clinical characteristics and investigate the association of 
LVEF with CIN and long-term mortality following CAG/PCI 
in patients with HF. Our data showed that patients with lower 
LVEF were more likely to have comorbidities and develop 
CIN. However, advanced HF was significantly associated 
with an increased risk of CIN. In addition, age .75 years, 
Table 2 incidence of Cin and in-hospital outcomes between left 
ventricular ejection fraction groups
Variables, n (%) HFrEF 
(N=207)
HFmrEF 
(N=238)
HFpEF 
(N=1,202)
P-value
Cin0.5 or 25% 38 (18.4) 52 (21.8) 135 (11.2) ,0.001
Cin0.3 or 50% 29 (14.0) 38 (16.0) 78 (6.5) ,0.001
Cin0.5 16 (7.7) 22 (9.2) 37 (3.1) ,0.001
Death 12 (5.8) 13 (5.5) 12 (1.0) ,0.001
hypotension 23 (11.1) 22 (9.2) 25 (2.1) ,0.001
intra-aortic balloon pump 29 (14.0) 29 (12.2) 35 (2.9) ,0.001
Renal replacement therapy 7 (3.4) 6 (2.5) 9 (0.7) 0.002
Cerebrovascular events 2 (1.0) 3 (1.3) 7 (0.6) 0.485
Abbreviations: Cin, contrast-induced nephropathy; hFreF, heart failure with 
reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; 
hFpeF, heart failure with preserved ejection fraction.
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Figure 1 Incidence of CIN in different definitions between left ventricular ejection 
fraction groups.
Abbreviations: Cin, contrast-induced nephropathy; hFreF, heart failure with 
reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; 
hFpeF, heart failure with preserved ejection fraction; Ci-aKi, contrast-induced 
acute kidney injury.
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emergency PCI and use of IABP were the independent risk 
factors for CIN. It is noteworthy that reduced LVEF was 
an independent predictor of long-term mortality following 
CAG/PCI.
In recent years, the proportion of patients with HFpEF 
has increased significantly,21 with a prevalence of 71%–74% 
being reported in large-cohort studies from Western and 
Asians countries.22–24 Additionally, myocardial ischemia has 
been demonstrated as the major etiology of HF.25,26 However, 
the incidence of HFpEF among these patients following 
CAG/PCI has not been analyzed. As observed in our analysis, 
the incidence of HFpEF was highest in the study population 
(72.98%), which was similar to the prior analyses. The high 
prevalence of HFpEF suggests that it should be given high 
priority in risk assessment.
Characteristics of HFmrEF were demonstrated to be 
intermediate between those of HFrEF and HFpEF.27 Similar 
results were found in the patients with HF following CAG/
Table 3 Association of left ventricular ejection fraction with CIN in different definition
Variables CIN0.5 or 25% CIN0.3 or 50% CIN0.5
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
hFpeF 1 Reference – 1 Reference – 1 Reference –
hFreF vs hFpeF 1.01 0.69–1.74 0.700 1.13 0.64–1.97 0.676 1.10 0.53–2.31 0.799
hFmreF vs hFpeF 1.31 0.87–1.96 0.194 1.43 0.88–2.33 0.145 1.58 0.84–2.98 0.158
age .75 years 1.73 1.20–2.49 0.004 1.77 1.51–2.72 0.010 2.07 1.18–3.62 0.011
hypertension 1.20 0.86–1.65 0.280 1.52 0.98–2.33 0.059 1.41 0.78–2.56 0.253
DM 1.08 0.77–1.52 0.644 0.79 0.51–1.22 0.289 0.64 0.35–1.17 0.146
Renal insufficiency 0.73 0.50–1.06 0.094 2.32 1.54–3.49 ,0.001 3.59 2.05–6.27 ,0.001
advanced hF 1.54 1.07–2.22 0.019 1.63 1.03–2.58 0.036 2.03 1.06–3.89 0.033
Prior Mi 0.90 0.55–1.48 0.685 0.80 0.42–1.53 0.505 0.61 0.23–1.57 0.303
emergency PCi 2.83 1.93–4.14 ,0.001 2.80 1.78–4.40 ,0.001 2.93 1.63–5.28 ,0.001
stains 0.71 0.34–1.47 0.351 0.36 0.16–0.78 0.009 0.23 0.09–0.59 0.002
Diuretics 1.73 1.21–2.47 0.003 1.80 1.17–2.77 0.007 1.41 0.79–2.51 0.243
CM volume .100 ml 1.21 0.89–1.66 0.223 1.36 0.91–2.03 0.134 1.52 0.87–2.65 0.142
hypotension 1.28 0.68–2.39 0.445 1.67 0.85–3.31 0.138 2.29 1.04–5.04 0.04
iaBP 2.45 1.44–4.19 ,0.001 3.65 2.08–6.40 ,0.001 3.83 1.95–7.51 ,0.001
Abbreviations: CIN, contrast-induced nephropathy; OR, odds ratio; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure 
with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; DM, diabetes mellitus; hF, heart failure; Mi, myocardial infarction; PCi, percutaneous 
coronary intervention; CM, contrast medium; iaBP, intra-aortic balloon pump.
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Figure 2 Cumulative rate of all-cause mortality during the follow-up in patients with 
hFreF, hFmreF and hFpeF.
Abbreviations: hFreF, heart failure with reduced ejection fraction; hFmreF, heart 
failure with mid-range ejection fraction; hFpeF, heart failure with preserved ejection 
fraction.
Table 4 association between left ventricular ejection fraction 
and long-term mortality
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
hFpeF 1 Reference – 1 Reference –
hFreF vs hFpeF 3.42 2.9–5.35 ,0.001 2.88 1.77–4.69 ,0.001
hFmreF vs hFpeF 2.22 1.39–3.55 ,0.001 1.55 0.95–2.53 0.079
age .75 years 2.52 1.69–3.76 ,0.001 1.76 1.14–2.72 0.011
hypertension 1.00 0.68–1.46 0.998 0.91 0.61–1.37 0.66
Renal insufficiency 4.55 3.14–6.60 ,0.001 3.04 2.02–4.56 ,0.001
DM 1.61 1.09–2.37 0.017 1.38 0.93–2.07 0.113
iaBP 4.66 2.90–7.49 ,0.001 2.00 1.18–3.38 0.01
advanced hF 2.19 1.51–3.17 ,0.001 0.83 0.53–1.30 0.409
anemia 2.04 1.41–2.96 ,0.001 1.46 0.99–2.17 0.056
emergency PCi 3.35 2.25–5.00 ,0.001 2.49 1.55–4.00 ,0.001
Abbreviations: HR, hazard ratio; CI, confidence interval; HFpEF, heart failure with 
preserved ejection fraction; hFreF, heart failure with reduced ejection fraction; 
hFmreF, heart failure with mid-range ejection fraction; DM, diabetes mellitus; 
iaBP, intra-aortic balloon pump; hF, heart failure; PCi, percutaneous coronary 
intervention.
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PCI. Our present study indicated that HFmrEF patients were 
closer to the HFrEF patients in terms of use of diuretics and 
IABP and presence of comorbidities, such as advanced HF, 
renal insufficiency and hypotension, but closer to the HFpEF 
in terms of use of statins, all of which have been demonstrated 
as contributing factors for CIN.19,28 Moreover, patients with 
HFmrEF were more likely to undergo emergency PCI than 
other groups. Based on those characteristics, the incidence 
of CIN was highest in this particular population. In recent 
years, CIN has been reported as the third most common 
cause of hospital-acquired renal failure.3 Therefore, effec-
tive pre-procedural identification of patients at high risk of 
CIN is vital.
LVEF is the most widely used parameter to evaluate 
cardiac functions associated with hemodynamic instability, 
and consequently causes inadequate renal perfusion. How-
ever, the association between LVEF and CIN still remains 
controversial. An observational study by Shacham et al11 
included 386 patients undergoing PCI and found that patients 
with worsened LVEF had significantly higher rate of CIN 
compared with those with LVEF $45% (14.4% vs 5.7%; 
P=0.02). Moreover, worsened LVEF was an independent 
predictor of CIN. Similar results were found in another 
extensive cohort study, and a risk score of CIN was named 
AGEF, including advanced age, depressed LVEF and 
reduced eGFR.12,29 However, studies conducted by Kurtul 
Figure 3 Cumulative all-cause mortality of CIN and Non-CIN within the definition of (A) Cin0.5 or 25%, (B) Cin0.3 or 50%, (C) Cin0.5.
Abbreviation: Cin, contrast-induced nephropathy.
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et al13 and Barbieri et al14 showed an opposite effect after 
adjusting for several confounders. As observed in all the 
above-mentioned studies, only a small number of patients 
with HF were included, and consequently, those studies were 
unable to analyze the association between LVEF and CIN. 
Furthermore, HF, as an important risk factor of CIN,8,19 was 
not included in the multivariate analysis. In contrast, our 
study included sufficient patients with HF and adjusted for 
the potential confounders to investigate the association of 
LVEF with CIN following CAG/PCI.
Previous studies indicated that the incidence of CIN in 
those with segment elevation myocardial infarction after 
PCI to be ranged from 10% to 20%. The potential factors 
such as impaired hemodynamic stability, large CM dose 
and insufficient prophylactic hydration led to higher risk 
of CIN in this particular group. In addition, inflammatory 
response and neurohumoral factors were also involved in 
this progress.30 Therefore, emergency PCI was significantly 
and independently related to the risk of CIN.31,32 Recently, 
Duan et al33 developed a simple model for early prediction of 
CIN, which indicated that emergency PCI was a significant 
influencing factor in this model. Similarly, emergency PCI 
increased the risk of CIN in our analysis. Therefore, more 
prophylactic measures and attention should be paid in this 
particular population.
The physiopathology of CIN remains poorly understood. 
Nevertheless, hemodynamic deterioration plays a significant 
role in the process. Worsened cardiac function contributes 
to the hemodynamic instability, which reduces effective 
renal blood flow, consequently trigging renin–angiotensin, 
activating sympathetic nervous system and increasing 
inflammatory factors and oxygen radical levels, all of which 
contribute to the development of CIN.34 Therefore, among 
the eight variables from a classical risk assessment model 
for CIN, three (hypotension, advanced HF and use of IABP) 
are directly reflecting worsened cardiac function.8 In addi-
tion, a high NYHA class reflects not only advanced HF but 
also adverse hemodynamic parameters35 which accelerate 
the renal hypoperfusion and potentiate CIN. Therefore, it 
is likely that advanced HF plays an important role in the 
development of CIN in patients with HF.
Furthermore, previous studies suggested that patients 
with HFrEF experienced higher mortality compared to those 
with HFpEF, whereas others have indicated similar outcomes 
among the groups.36–38 The marked disparity in long-term 
prognosis may contribute to the different inclusion criteria 
and various cut-offs of LVEF to define the type of HF. 
According to the classification of HF from guideline,10 our 
data demonstrated that HFrEF in patients increased the 
risk of all-cause mortality. Therefore, early identification 
of patients at high risk of mortality may assist in directing 
treatment.
limitations
There are several limitations in this study. First, this was a pro-
spective, observational and a single-center study. Therefore, 
the risk of bias cannot be ruled out, although we attempted 
to adjust for the confounding factors. Therefore, large-scale 
multicenter clinical trials are needed before these conclusions 
can be applied elsewhere. Second, variation in measurement 
times may lead to missed post-procedure peak levels of crea-
tinine and may underestimate the true incidence of contrast-
induced acute kidney injury. Third, as the study was limited 
to patients with HF, we were unable to extend the results to 
patients without HF. Fourth, the diagnosis of HF was based 
on the clinical evaluation, which has limited reliability.
Conclusion
Our data indicated that in patients with HF, not worsened 
LVEF but advanced HF was significantly associated with an 
increased risk of CIN following CAG/PCI. In addition, the 
reduced LVEF (HFrEF group) was an independent predictor 
of long-term mortality. The predictive value of worsened 
LVEF and advanced HF for CIN and mortality following 
cardiac catheterization needs to be investigated in patients 
with HF in large multicenter clinical trials.
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